Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2018-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the study drug, BMS-986142, is safe and
effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate
response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors.
Patients who qualify will be randomized to either one of 3 doses of BMS-986142 or placebo in
1:1:1 randomization for 12 weeks. Disease activity and safety will be assessed over the
course of the study.